Abstract 16974: Gender Differences in Patients Undergoing Transcatheter Aortic Valve Replacement: a Single Center Experience
Background: Current data suggest that women experience different outcomes to men following transcatheter aortic valve replacement (TAVR). We reviewed the Mount Sinai valve database to compare men and women undergoing TAVR according to procedural characteristics and outcomes.
Methods: 124 patients underwent TAVR at Mount Sinai from May 2012-2014. All patients received Edwards Sapien valves. Follow-up was conducted at 30-days.
Results: Women accounted for 61% (n=76) of the TAVR cohort. The mean age of women was 80.7, and 82.2 for men (p=0.30). Men were more likely to have undergone previous cardiac bypass surgery and were more likely to be on dialysis and have a pacemaker or intra-cardiac defibrillator in-situ (27.1% vs. 7.9%, p=0.004). Women had lower baseline hemoglobin. These disparities did not translate to differences in STS Risk Score or EuroScore. In women, the aortic annulus (21.2mm vs. 23.4mm, p<0.0001), left atrial (24.6mm vs. 27.2mm, p = 0.02) and left ventricular (3.09mm vs. 4.11mm, p<0.001) areas were smaller, as was the ilio-femoral artery diameter (7.4mm vs. 8.03mm, p=0.02). In contrast, men had a lower left ventricular ejection fraction (49.9% vs. 57.6%, p=0.004) and mean aortic valve gradient (43.5mmHg vs. 48.8mmHg, p=0.004). Procedural length did not differ between genders, nor did the method of approach. Women were less likely to experience conduction complications requiring pacemaker insertion both intra-procedurally (2.6% vs. 12.5%, p=0.03) and 30-days post-discharge (2.7% vs. 13.2%, p = 0.03). Women were more likely to receive in-hospital transfusion (51.3% vs. 18.8%, p=0.0003), but mortality rates did not differ between genders (7.0% vs. 6.7%, p=0.5).
Conclusion: Despite discrepancies in some important pre-procedural parameters, as well as rates of post-procedural conduction abnormalities and in-hospital transfusion, these did not translate into differences in mortality rates between genders in patients undergoing TAVR.
Author Disclosures: J.L. Warren: None. U. Baber: None. J. Yu: None. M. Aquino: None. A. Bhat: None. S. Basnet: None. G. Dangas: Research Grant; Modest; Sanofi-Aventis, BMS, Daichi-Sankyo & Eli Lilly partnership. Consultant/Advisory Board; Modest; Johnson & Johnson, sanofi-aventis, Covidien, Medicines Co, Merck, CSL Bhering, Astra-Zeneca, Medtronic, Abbott, Bayer, Boston Scientific, Osprey Medical, GE Healthcare. R. Mehran: Research Grant; Modest; BMS/sanofi-aventis, lilly/DSI, Lilly/DSI, The Medicines Company, Regado, STENTYS. Honoraria; Modest; Janssen J+J, Maya Medical, Sanofi, Boston Scientific, Merck, AstraZeneca, Abbott Vascular, Covidien, CSL Berhing. R. Pyo: None. J. Kovacic: Research Grant; Modest; Astrazenaca. Speakers Bureau; Modest; Astrazenaca. S.K. Sharma: Speakers Bureau; Modest; BSC, Abbott, Medicine Co., Lilly/Daiichi-Sankyo. A.S. Kini: None.
- © 2014 by American Heart Association, Inc.